Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program
Merck announced restructuring (cost efficiency) program which is likely to benefit the company in the long run on the back delaying approval of Sugammadex, Odanacatib and Suvorexant from US regulatory authorities. Cost efficiency measures ($2.5b cost saving by 2015) announced by the Company through workforce reduction across all functional divisions, head quarter relocation, out-licensing/discontinuation of some late stage programs. More focused attention on therapy areas where Merck has proven its abilities irrespective of unmet need and exploration of business commercial and innovation opportunities outside the company will redefine the Company for a better outlook. New R&D strategy will also have reduced focus on building Platform technologies.
